Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept withdrawal and retreatment study in non-radiographic axial spondyloarthritis responders
2015-000541-24Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept in non-radiographic axial spondyloarthritis (nr-axSpA), axial spondyloarthritis (axSpA) and spondyloarthritis (SpA) (2 arms), sponsored by Pfizer. Primary endpoint: Occurrence of flare within 40 weeks after etanercept withdrawal. Started Sep 2015; status: completed.
02
Drugs
etanercept
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)axial spondyloarthritis (axSpA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2015-000541-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000541-24.